메뉴 건너뛰기




Volumn 30, Issue 4, 2013, Pages

Comparison of serious adverse reactions between thalidomide and lenalidomide: Analysis in the French Pharmacovigilance database

Author keywords

Lenalidomide; Serious adverse drug reactions; Thalidomide

Indexed keywords

ALLOPURINOL; AMOXICILLIN; BORTEZOMIB; CEFIXIME; CLAVULANIC ACID; CORTICOSTEROID; ESOMEPRAZOLE; GABAPENTIN; LENALIDOMIDE; MELPHALAN; METRONIDAZOLE; NICORANDIL; PHENOBARBITAL; TAMSULOSIN; THALIDOMIDE; VANCOMYCIN; DRUG DERIVATIVE;

EID: 84891883856     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0733-2     Document Type: Review
Times cited : (5)

References (45)
  • 1
    • 33746336252 scopus 로고    scopus 로고
    • Thalidomide and lenalidomide in the treatment of multiple myeloma
    • DOI 10.1016/j.ejca.2006.04.004, PII S095980490600308X
    • Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer. 2006;42:1612-22. (Pubitemid 44118763)
    • (2006) European Journal of Cancer , vol.42 , Issue.11 , pp. 1612-1622
    • Kumar, S.1    Rajkumar, S.V.2
  • 2
    • 2142825614 scopus 로고    scopus 로고
    • Thalidomide: An old drug with new clinical applications
    • DOI 10.1517/14740338.3.1.47
    • Laffite E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf. 2004;3(1):47-56. (Pubitemid 38765186)
    • (2004) Expert Opinion on Drug Safety , vol.3 , Issue.1 , pp. 47-56
    • Laffitte, E.1    Revuz, J.2
  • 3
    • 61349118005 scopus 로고    scopus 로고
    • Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
    • 18774632 10.1016/j.blre.2008.07.003 1:CAS:528:DC%2BD1MXmtlWltLo%3D
    • Palumbo A, Dimopoulos M, San Miguel J, et al. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev. 2009;23:87-93.
    • (2009) Blood Rev , vol.23 , pp. 87-93
    • Palumbo, A.1    Dimopoulos, M.2    San Miguel, J.3
  • 4
    • 0036381106 scopus 로고    scopus 로고
    • Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells
    • 12296856 10.1046/j.1365-2249.2002.01954.x 1:CAS:528:DC%2BD38XotlGgsr0%3D
    • Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol. 2002;130:75-84.
    • (2002) Clin Exp Immunol , vol.130 , pp. 75-84
    • Marriott, J.B.1    Clarke, I.A.2    Dredge, K.3    Muller, G.4    Stirling, D.5    Dalgleish, A.G.6
  • 6
    • 33750607347 scopus 로고    scopus 로고
    • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    • 16840727 10.1182/blood-2006-04-015909 1:CAS:528:DC%2BD28Xht1ahsLzO
    • Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458-64.
    • (2006) Blood , vol.108 , Issue.10 , pp. 3458-3464
    • Richardson, P.G.1    Blood, E.2    Mitsiades, C.S.3
  • 10
    • 0034619028 scopus 로고    scopus 로고
    • Adverse drug reactions: Definitions, diagnosis and management
    • 11072960 10.1016/S0140-6736(00)02799-9 1:CAS:528:DC%2BD3cXot1agsr8%3D
    • Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet. 2000;356(9237):1255-9.
    • (2000) Lancet , vol.356 , Issue.9237 , pp. 1255-1259
    • Edwards, I.R.1    Aronson, J.K.2
  • 11
    • 0032991290 scopus 로고    scopus 로고
    • The Medical Dictionary for Regulatory Activities (MedDRA)
    • DOI 10.2165/00002018-199920020-00002
    • Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109-17. (Pubitemid 29101275)
    • (1999) Drug Safety , vol.20 , Issue.2 , pp. 109-117
    • Brown, E.G.1    Wood, L.2    Wood, S.3
  • 12
    • 0022036232 scopus 로고
    • Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France
    • Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie. 1985;40(2):111-8.
    • (1985) Thérapie , vol.40 , Issue.2 , pp. 111-118
    • Bégaud, B.1    Evreux, J.C.2    Jouglard, J.3    Lagier, G.4
  • 13
    • 78649707335 scopus 로고    scopus 로고
    • Lenalidomide mode of action: Linking bench and clinical findings
    • 21126632 10.1016/S0268-960X(10)70004-7
    • Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010;24(Suppl 1):S13-9.
    • (2010) Blood Rev , vol.24 , Issue.SUPPL. 1
    • Davies, F.1    Baz, R.2
  • 15
    • 33646744337 scopus 로고    scopus 로고
    • Under-reporting of adverse drug reactions: A systematic review
    • 16689555 10.2165/00002018-200629050-00003
    • Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-96.
    • (2006) Drug Saf , vol.29 , Issue.5 , pp. 385-396
    • Hazell, L.1    Shakir, S.A.2
  • 17
    • 84870699940 scopus 로고    scopus 로고
    • Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?
    • 22961933 10.1002/pds.3333
    • Paludetto MN, Olivier-Abbal P, Montastruc JL. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France? Pharmacoepidemiol Drug Saf. 2012;21(12):1289-94.
    • (2012) Pharmacoepidemiol Drug Saf , vol.21 , Issue.12 , pp. 1289-1294
    • Paludetto, M.N.1    Olivier-Abbal, P.2    Montastruc, J.L.3
  • 18
    • 0002656565 scopus 로고
    • Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs
    • K.D. Rainsford G. Velo (eds) 6 Raven Press New York
    • Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. In: Rainsford KD, Velo GP, editors. Advances in inflammation research, vol. 6. New York: Raven Press; 1984. p. 1-6.
    • (1984) Advances in Inflammation Research , pp. 1-6
    • Weber, J.C.P.1
  • 19
    • 77949890246 scopus 로고    scopus 로고
    • Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: A comparative analysis of 411 patients
    • 20008302 10.1182/blood-2009-08-239046 1:CAS:528:DC%2BC3cXjtVWruro%3D
    • Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115(7):1343-50.
    • (2010) Blood , vol.115 , Issue.7 , pp. 1343-1350
    • Gay, F.1    Hayman, S.R.2    Lacy, M.Q.3
  • 20
    • 77956928323 scopus 로고    scopus 로고
    • Multiple myeloma: Management of adverse events
    • 19582597 10.1007/s12032-009-9262-4 1:STN:280:DC%2BC3cjmtVWlsg%3D%3D
    • Gay F, Palumbo A. Multiple myeloma: management of adverse events. Med Oncol. 2010;27(3):646-53.
    • (2010) Med Oncol , vol.27 , Issue.3 , pp. 646-653
    • Gay, F.1    Palumbo, A.2
  • 22
    • 77952817334 scopus 로고    scopus 로고
    • Management of treatment-related adverse events in patients with multiple myeloma
    • 20472185 10.1016/S0305-7372(10)70009-8
    • Mateos MV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010;36(Suppl 2):S24-32.
    • (2010) Cancer Treat Rev , vol.36 , Issue.SUPPL. 2
    • Mateos, M.V.1
  • 23
    • 79955646392 scopus 로고    scopus 로고
    • Lenalidomide treatment for patients with multiple myeloma: Diagnosis and management of most frequent adverse events
    • Pérez Persona E, Mesa MG, García Sánchez PJ, González Rodríguez AP. Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events. Adv Ther. 2011;28(Suppl 1):11-6.
    • (2011) Adv Ther , vol.28 , Issue.SUPPL. 1 , pp. 11-16
    • Pérez Persona E, M.1
  • 25
    • 77449111211 scopus 로고    scopus 로고
    • Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
    • 19965623 10.1182/blood-2009-05-221077 1:CAS:528:DC%2BC3cXhsFegsLY%3D
    • Pal R, Monaghan SA, Hassett AC, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 2010;115(3):605-14.
    • (2010) Blood , vol.115 , Issue.3 , pp. 605-614
    • Pal, R.1    Monaghan, S.A.2    Hassett, A.C.3
  • 26
    • 77954086364 scopus 로고    scopus 로고
    • Management of disease- and treatment-related complications in patients with multiple myeloma
    • 20467920 10.1007/s12032-010-9542-z 1:CAS:528:DC%2BC3cXnsFylsr0%3D
    • Gay F, Palumbo A. Management of disease- and treatment-related complications in patients with multiple myeloma. Med Oncol. 2010;27:S43-52.
    • (2010) Med Oncol , vol.27
    • Gay, F.1    Palumbo, A.2
  • 27
    • 55449104900 scopus 로고    scopus 로고
    • Images in HIV/AIDS. Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection
    • 18975442
    • Tebruegge M, Pantazidou A. Images in HIV/AIDS. Stevens-Johnson syndrome associated with thalidomide treatment in HIV infection. AIDS Read. 2008;18(10):519-20.
    • (2008) AIDS Read , vol.18 , Issue.10 , pp. 519-520
    • Tebruegge, M.1    Pantazidou, A.2
  • 28
    • 67349247571 scopus 로고    scopus 로고
    • Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy
    • 19052692 10.1007/s12185-008-0220-2
    • Colagrande M, Di Ianni M, Coletti G, et al. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. Int J Hematol. 2009;89(1):76-9.
    • (2009) Int J Hematol , vol.89 , Issue.1 , pp. 76-79
    • Colagrande, M.1    Di Ianni, M.2    Coletti, G.3
  • 29
    • 77649281023 scopus 로고    scopus 로고
    • Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: A case report
    • 19693501 10.1007/s00277-009-0810-y
    • Eo WK, Kim SH, Cheon SH, et al. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report. Ann Hematol. 2010;89(4):421-2.
    • (2010) Ann Hematol , vol.89 , Issue.4 , pp. 421-422
    • Eo, W.K.1    Kim, S.H.2    Cheon, S.H.3
  • 30
    • 0032858116 scopus 로고    scopus 로고
    • Thalidomide-induced toxic epidermal necrolysis
    • DOI 10.1592/phco.19.15.1177.30571
    • Horowitz SB, Stirling AL. Thalidomide-induced toxic epidermal necrolysis. Pharmacotherapy. 1999;19(10):1177-80. (Pubitemid 29455940)
    • (1999) Pharmacotherapy , vol.19 , Issue.10 , pp. 1177-1180
    • Horowitz, S.B.1    Stirling, A.L.2
  • 31
    • 0034727058 scopus 로고    scopus 로고
    • Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
    • 11012329 10.1056/NEJM200009283431315 1:STN:280:DC%2BD3cvmtVSisA%3D%3D
    • Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med. 2000;343(13):972-3.
    • (2000) N Engl J Med , vol.343 , Issue.13 , pp. 972-973
    • Rajkumar, S.V.1    Gertz, M.A.2    Witzig, T.E.3
  • 32
    • 58149343983 scopus 로고    scopus 로고
    • Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients
    • 19047275 10.1200/JCO.2008.20.3737
    • Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol. 2009;27(1):156-7.
    • (2009) J Clin Oncol , vol.27 , Issue.1 , pp. 156-157
    • Castaneda, C.P.1    Brandenburg, N.A.2    Bwire, R.3    Burton, G.H.4    Zeldis, J.B.5
  • 33
    • 0034745883 scopus 로고    scopus 로고
    • Thalomid (Thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing
    • 11235821 10.2165/00002018-200124020-00002 1:CAS:528:DC%2BD3MXhs1Whu7w%3D
    • Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf. 2001;24(2):87-117.
    • (2001) Drug Saf , vol.24 , Issue.2 , pp. 87-117
    • Clark, T.E.1    Edom, N.2    Larson, J.3    Lindsey, L.J.4
  • 34
    • 78649715070 scopus 로고    scopus 로고
    • Lenalidomide: An update on evidence from clinical trials
    • 21126633 10.1016/S0268-960X(10)70005-9
    • Dimopoulos MA, Terpos E. Lenalidomide: an update on evidence from clinical trials. Blood Rev. 2010;24(Suppl 1):S21-6.
    • (2010) Blood Rev , vol.24 , Issue.SUPPL. 1
    • Dimopoulos, M.A.1    Terpos, E.2
  • 35
    • 33646494190 scopus 로고    scopus 로고
    • Lenalidomide and venous thrombosis in multiple myeloma
    • 16696148 10.1056/NEJMc053530
    • Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354(19):2079-80.
    • (2006) N Engl J Med , vol.354 , Issue.19 , pp. 2079-2080
    • Rajkumar, S.V.1    Blood, E.2
  • 36
    • 44449135859 scopus 로고    scopus 로고
    • Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers
    • 10.1016/j.patbio.2008.02.013 1:STN:280:DC%2BD1cvitlCktw%3D%3D
    • Drouet L. Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers. Pathol Biol (Paris). 2008;56(4):195-204.
    • (2008) Pathol Biol (Paris) , vol.56 , Issue.4 , pp. 195-204
    • Drouet, L.1
  • 37
    • 76549137222 scopus 로고    scopus 로고
    • Peripheral neuropathy and new treatments for multiple myeloma: Background and practical recommendations
    • 20139393 10.3324/haematol.2009.012674 1:CAS:528:DC%2BC3cXht1yjtr%2FK
    • Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311-9.
    • (2010) Haematologica , vol.95 , Issue.2 , pp. 311-319
    • Mohty, B.1    El-Cheikh, J.2    Yakoub-Agha, I.3    Moreau, P.4    Harousseau, J.L.5    Mohty, M.6
  • 38
    • 78049528177 scopus 로고    scopus 로고
    • Treatment-related peripheral neuropathy in multiple myeloma: The challenge continues
    • 20932799 10.1016/S1470-2045(10)70068-1 1:CAS:528:DC%2BC3cXhtlKmtrnF
    • Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086-95.
    • (2010) Lancet Oncol , vol.11 , Issue.11 , pp. 1086-1095
    • Delforge, M.1    Bladé, J.2    Dimopoulos, M.A.3
  • 39
    • 79958007072 scopus 로고    scopus 로고
    • Practical management of adverse events in multiple myeloma: Can therapy be attenuated in older patients?
    • 21497966 10.1016/j.blre.2011.03.005 1:CAS:528:DC%2BC3MXntVeltr0%3D
    • Palumbo A, Mateos MV, Bringhen S, San Miguel JF. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev. 2011;25(4):181-91.
    • (2011) Blood Rev , vol.25 , Issue.4 , pp. 181-191
    • Palumbo, A.1    Mateos, M.V.2    Bringhen, S.3    San Miguel, J.F.4
  • 40
    • 33749051832 scopus 로고    scopus 로고
    • Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
    • DOI 10.1200/JCO.2006.05.6689
    • Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patters of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24(27):4507-14. (Pubitemid 46630990)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.27 , pp. 4507-4514
    • Mileshkin, L.1    Stark, R.2    Day, B.3    Seymour, J.F.4    Zeldis, J.B.5    Prince, H.M.6
  • 41
    • 84860709392 scopus 로고    scopus 로고
    • Lenalidomide maintenance after stemcell transplantation for multiple myeloma
    • 22571202 10.1056/NEJMoa1114138 1:CAS:528:DC%2BC38Xnt1Gjsrs%3D
    • Attal M, Lauwers VC, Marit G, et al. Lenalidomide maintenance after stemcell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
    • (2012) N Engl J Med , vol.366 , Issue.19 , pp. 1782-1791
    • Attal, M.1    Lauwers, V.C.2    Marit, G.3
  • 42
    • 84860741191 scopus 로고    scopus 로고
    • Lenalidomide after stem-cell transplantation for multiple myeloma
    • 22571201 10.1056/NEJMoa1114083 1:CAS:528:DC%2BC38Xnt1Gjsro%3D
    • McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
    • (2012) N Engl J Med , vol.366 , Issue.19 , pp. 1770-1781
    • McCarthy, P.L.1    Owzar, K.2    Hofmeister, C.C.3
  • 43
    • 84860744403 scopus 로고    scopus 로고
    • Continuous lenalidomide treatment for newly diagnosed multiple myeloma
    • 22571200 10.1056/NEJMoa1112704 1:CAS:528:DC%2BC38Xnt1Gjsrw%3D
    • Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
    • (2012) N Engl J Med , vol.366 , Issue.19 , pp. 1759-1769
    • Palumbo, A.1    Hajek, R.2    Delforge, M.3
  • 44
    • 84858824788 scopus 로고    scopus 로고
    • Second malignancies after multiple myeloma: From 1960s to 2010s
    • 22310913 10.1182/blood-2011-12-381426 1:CAS:528:DC%2BC38XkvFalt7g%3D
    • Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012;119(12):2731-7.
    • (2012) Blood , vol.119 , Issue.12 , pp. 2731-2737
    • Thomas, A.1    Mailankody, S.2    Korde, N.3    Kristinsson, S.Y.4    Turesson, I.5    Landgren, O.6
  • 45
    • 84891887368 scopus 로고    scopus 로고
    • European Medicines Agency. Revlimid: EPAR (European Public Assessment Report)-Scientific discussion (26/6/2007) Accessed April 4, 2013
    • European Medicines Agency. Revlimid: EPAR (European Public Assessment Report)-Scientific discussion (26/6/2007) http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Scientific-Discussion/human/000717/WC500056022.pdf. Accessed April 4, 2013.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.